Leadership Overview
Tabuk Manufacturing has 4 executives leading key functions including corporate strategy, executive operations, market expansion, and financial management.
Committed to delivering high-quality, cost-effective healthcare solutions, Tabuk Manufacturing drives pharmaceutical innovation across the MENA region to improve patient outcomes in cardiovascular, respiratory, and central nervous system therapeutic areas.
Committed to delivering high-quality, cost-effective healthcare solutions, Tabuk Manufacturing drives pharmaceutical innovation across the MENA region to improve patient outcomes in cardiovascular, respiratory, and central nervous system therapeutic areas.
Leadership Roles at Tabuk Manufacturing
Ismail Shehada - Chief Executive Officer
Ismail Shehada, the Chief Executive Officer at Tabuk Manufacturing, directs the overarching corporate strategy and long-term vision for the organization. By overseeing the development of generic pharmaceutical portfolios, the Chief Executive Officer ensures alignment with the healthcare needs of the MENA region. This leadership role involves managing complex regulatory environments while maintaining cost-effective production standards for cardiovascular and respiratory medications. Ismail Shehada actively coordinates with the Board to optimize market penetration and operational efficiency across diverse therapeutic sectors. Through rigorous oversight of manufacturing quality and supply chain integrity, the Chief Executive Officer secures the company's competitive position in regulated markets. By fostering partnerships with regional health authorities, the Chief Executive Officer expands the reach of essential treatments. Ultimately, the Chief Executive Officer drives sustainable growth and maintains the reputation of the firm as a leader in the pharmaceutical industry.
Doaa Bugis - Chief Executive Officer Office Manager
Doaa Bugis, the Chief Executive Officer Office Manager at Tabuk Manufacturing, coordinates the administrative infrastructure and executive workflows necessary for seamless corporate governance. By managing the daily operations of the executive office, the Chief Executive Officer Office Manager facilitates communication between senior leadership and departmental heads. This role involves organizing high-level meetings, tracking strategic initiatives, and ensuring that the executive team remains focused on core business objectives like the production of GI and diabetes pharmaceuticals. Doaa Bugis maintains the integrity of internal processes, allowing the leadership team to execute complex projects with precision. By streamlining information flow, the Chief Executive Officer Office Manager supports the rapid decision-making required in the fast-paced pharmaceutical sector. Through meticulous attention to detail, the Chief Executive Officer Office Manager enhances the overall productivity of the executive suite, ensuring that all administrative functions align with the broader mission of delivering affordable healthcare solutions.
Saad Stephan - Chief Financial Officer
Saad Stephan, the Chief Financial Officer at Tabuk Manufacturing, manages the fiscal health and capital allocation strategies required to sustain large-scale pharmaceutical production. By overseeing financial planning, budgeting, and risk management, the Chief Financial Officer ensures that the company maintains the liquidity necessary for research and development in the central nervous system and cardiovascular sectors. This leadership role involves monitoring regional economic shifts and adjusting financial models to protect profit margins in the competitive MENA market. Saad Stephan provides the Board with critical insights into cost structures and investment returns, enabling informed decision-making regarding manufacturing expansion. By optimizing the capital structure, the Chief Financial Officer supports the long-term viability of the business. Through rigorous financial oversight and compliance with international accounting standards, the Chief Financial Officer secures the fiscal foundation of the organization. Ultimately, the Chief Financial Officer drives financial stability and enables the company to continue delivering affordable, high-quality medications.
Hatem Reda - Chief Marketing Officer
Hatem Reda, the Chief Marketing Officer at Tabuk Manufacturing, architects the commercial strategy and brand positioning for the company's extensive pharmaceutical portfolio. By overseeing market research and regional outreach, the Chief Marketing Officer identifies growth opportunities within the MENA region for musculoskeletal and infection-related treatments. This leadership role involves crafting targeted campaigns that communicate the value of cost-effective, high-quality medications to healthcare providers and institutional buyers. Hatem Reda collaborates with sales teams to ensure that product messaging resonates with the specific needs of diverse therapeutic markets. By analyzing market trends and competitor activity, the Chief Marketing Officer adjusts promotional tactics to maximize market share. Through the implementation of data-driven marketing initiatives, the Chief Marketing Officer strengthens the presence of the company in regulated markets. Ultimately, the Chief Marketing Officer drives revenue growth by ensuring that the pharmaceutical offerings remain the preferred choice for patients and medical professionals alike.
Explore Leadership Teams in Manufacturing
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.
Company Leadership TI
RN
FA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society. (Nasdaq: PCRX) is a provider of non-opioid pain management and regenerative health solutions manufacturing.
Company Leadership
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
SP
CS
MD
Frequently Asked Questions Regarding Tabuk Manufacturing Top Executives and Leadership Team
